Blase Polite to Imatinib Mesylate
This is a "connection" page, showing publications Blase Polite has written about Imatinib Mesylate.
Connection Strength
0.066
-
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
Score: 0.066